KalVista is developing novel plasma kallikrein inhibitors, which represent a new approach to the treatment of DME, the leading cause of adult visual loss in developed countries. These compounds have been advanced based on the Company’s deep expertise in the development of serine protease inhibitors, which can be applied to indications in ophthalmology and more broadly.

Latest News
KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema
KalVista Pharmaceuticals Brings Expertise to New European Consortium Focused on the Discovery and Development of Novel Eye Therapeutics
Registered Office: Phi House, Enterprise Road, Southampton Science Park, Southampton, SO16 7NS. Registered in England. Registered No: 07543947